RelatedLinks

May 26th

May 18th

  • Rimonabant - Wikipedia, the free encyclopedia
  • Preclinical Characterizati on of A-582941: A Novel ?7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enha ncing Properties: Karin R. Tietje 1 , David J. Anderson 1 , R. Scott Bitner 1 , Eric A. Blomme 2 , Paul J. Brackemeyer 5 , Clark A. Briggs 1 , Kaitlin E. Browman 1 , Dagmar Bury 7 , Peter Curzon 1 , Karla U. Drescher 3 , Jennifer M. Frost 1 , Ryan M. Fryer 4 , Gerard B. Fox 1 , Jens Halvard Gronlien 1 , Monika Håkerud 1 , Earl J. Gubbins 1 , Sabine Halm 7 , Richard Harris 1 , Rosalind J. Helfrich 1 , Kathy L. Kohlhaas 1 , Devalina Law 5 , John Malysz 1 , Kennan C. Marsh 6 , Ruth L. Martin 4 , Michael D. Meyer 1 , Angela L. Molesky 1 , Arthur L. Nikkel 1 , Stephani Otte 1 , Liping Pan 6 , Pamela S. Puttfarcken 1 , Richard J. Radek 1 , Holly M. Robb 1 , Eva Spies 3 , Kirsten Thorin-Hagene 1 , Jeffrey F. Waring 2 , Hilde Ween 1 , Hongyu Xu 6 , Murali Gopalakrishnan 1 & William H. Bunnelle

April 20th

April 15th

March 11th

October 30th

September 24th

September 20th

August 12th

August 1st

February 24th

February 12th

    Video Buzz > Agonist

    Format: AVI | MPEG | Real | Quicktime | Window Media

    No Matching Video

    No video for Agonist is available at this time.

    Related Agonist News

    CHMP Recommends 'Januvia(R)'(sitagliptin), From MSD, For Restricted ... - Medical News Today

    Merck & Co., Inc. (Whitehouse Station, N.J., U.S.A.), which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP ...

    Sosei and Vectura Announce Start of Phase III Clinical Study With ... - Earthtimes

    Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC) announce the commencement of a Phase III clinical study by Novartis, with NVA237, a once-daily, long-acting muscarinic antagonist (LAMA) for the ...

    Role of ERK/MAPK in endothelin receptor signaling in human aortic ... - BioMed Central

    Endothelin-1 (ET-1) is a potent vasoactive peptide, which induces vasoconstriction and proliferation in vascular smooth muscle cells (VSMCs) through activation of endothelin type A (ETA) and type B (ETB) receptors. The extracellular signal-regulated ...

    Theravance Announces New Employment Inducement Awards - PR Inside

    SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 07/01/09 -- Theravance, Inc. (NASDAQ: THRX) today reported that equity awards were made to three new employees. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity awards were granted under the ...

    Schering-Plough Announces Phase II And III Data For Corifollitropin ... - Medical News Today

    Schering-Plough Corp., (NYSE: SGP) announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant ...

    Agonist Podcasts

    Do you prefer to listen to your agonist gossip? Check out Podzy Podcast Directory > Agonist.

    Agonist Products

    Looking for agonist related products, then look no further. Try our new Agonist Shop.


    Powered by Odin Assemble